California's insulin initiative is an ill-conceived idea, says analyst

According to a Sydbank analyst, the state’s intention to produce insulin also shouldn’t be viewed as potential competition for makers of the drug like Novo Nordisk.

Photo: Jacob Ehrbahn/Politiken

Although California is intending to produce insulin for its own population, efforts to meet demand will hardly be a match for the big drugmakers already supplying the state, says Sydbank analyst Søren Løntoft Hansen. In all likelihood, the end product would be both more expensive and based on older research.

In the analyst’s assessment, the initiative will therefore have little effect on Novo Nordisk.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs